LIGAND PHARMACEUTICALS (LGND)
US53220K5048 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 50.09M | 22.95M | 45.00M | 19.50M | 47.60M | |||
| Marketable Securities | 260.50M | 147.35M | 166.90M | 321.60M | 363.60M | |||
| Receivables | 28.43M | 39.31M | 35.00M | 91.60M | 59.10M | |||
| Inventories | 21.34M | 23.97M | 13.30M | 27.30M | 26.50M | |||
| Other Current Assets | 8.55M | 3.84M | 3.40M | 4.70M | 3.80M | |||
| Total Current Assets | 368.91M | 237.43M | 263.60M | 464.80M | 500.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 24.38M | 25.06M | 27.50M | 53.30M | 37.20M | |||
| Investments And Advances | 46.97M | 48.32M | N/A | N/A | N/A | |||
| Goodwill | 105.25M | 103.37M | 105.70M | 181.20M | 189.70M | |||
| Intangibles | 357.13M | 366.90M | 352.60M | 561.20M | 606.30M | |||
| Other Non-Current Assets | 11.22M | 6.14M | 13.30M | 37.20M | 28.60M | |||
| Total Non-Current Assets | 544.96M | 549.79M | 499.10M | 832.80M | 861.70M | |||
| TOTAL ASSETS | 913.87M | 787.22M | 762.70M | 1.30B | 1.36B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 3.00K | 7.00K | 76.70M | 0.00 | 6.60M | |||
| Accrued Expenses | 12.81M | 12.25M | 16.40M | 19.60M | 20.40M | |||
| Accounts Payable | 1.89M | 2.43M | 5.30M | 8.40M | 3.80M | |||
| Other Current Liabilities | 3.11M | 2.10M | 400.00K | 13.60M | 69.30M | |||
| Total Current Liabilities | 17.82M | 16.78M | 98.80M | 41.70M | 100.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 320.70M | 442.30M | |||
| Deferred Taxes/Income | 50.61M | 31.62M | 30.60M | 59.10M | 64.60M | |||
| Other Non-Current Liabilities | 38.92M | 37.90M | 35.80M | 55.00M | 45.80M | |||
| Total Non-Current Liabilities | 89.53M | 69.52M | 66.40M | 434.70M | 552.70M | |||
| TOTAL LIABILITIES | 107.35M | 86.30M | 165.20M | 476.40M | 652.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 589.15M | 503.02M | 450.90M | 449.10M | 392.00M | |||
| Additional Paid In Capital | 218.26M | 198.70M | 147.60M | 373.00M | 318.40M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 18.00K | 18.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -910.00K | -817.00K | -1.00M | -900.00K | -800.00K | |||
| Shares Outstanding | 17.92M | 17.56M | 17.00M | 16.80M | 16.10M | |||
| Tangible Book Value per Share | 19.20 | 13.14 | 8.19 | 4.69 | -5.37 | |||
| Total Shareholders' Equity | 806.52M | 700.91M | 597.50M | 821.20M | 709.50M | |||
| TOTAL LIABILITIES AND EQUITY | 913.87M | 787.22M | 762.70M | 1.30B | 1.36B | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.39 | 0.62 | |||
| Current Ratio | 20.70 | 14.15 | 2.67 | 11.15 | 5.00 | |||
| Return On Assets (ROA) | 10.54% | 6.63% | -4.38% | 4.40% | -0.22% | |||
| Return On Equity (ROE) | 11.95% | 7.44% | -5.59% | 6.95% | -0.42% | |||
| Return On Invested Capital (ROIC) | N/A | 1.01% | 0.36% | 4.96% | 0.54% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 1.29% | 0.52% | 6.81% | 0.81% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 5.97% | N/A | 36.15% | 12.50% | |||
All data in USD